Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D, Chataway J, Schmierer K. Pakpoor J, et al. Among authors: marta m. Neurol Neuroimmunol Neuroinflamm. 2015 Oct 1;2(6):e158. doi: 10.1212/NXI.0000000000000158. eCollection 2015 Dec. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26468472 Free PMC article.
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.
Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G. Kuhle J, et al. Among authors: marta m. Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13. Mult Scler. 2015. PMID: 25680984
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Giovannoni G, et al. Among authors: marta m. Mult Scler Relat Disord. 2015 Jul;4(4):329-33. doi: 10.1016/j.msard.2015.04.006. Epub 2015 May 8. Mult Scler Relat Disord. 2015. PMID: 26195051 Free article. Review.
Disease modification in advanced MS: Focus on upper limb function.
Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K. Dubuisson N, et al. Among authors: marta m. Mult Scler. 2017 Dec;23(14):1956-1957. doi: 10.1177/1352458517717811. Epub 2017 Jul 3. Mult Scler. 2017. PMID: 28669257 No abstract available.
Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.
Dubuisson N, Bauer A, Buckley M, Gilbert R, Paterson A, Marta M, Gnanapavan S, Turner B, Baker D, Giovannoni G, Schmierer K, Thomson A. Dubuisson N, et al. Among authors: marta m. Mult Scler Relat Disord. 2017 Oct;17:172-176. doi: 10.1016/j.msard.2017.08.002. Epub 2017 Aug 9. Mult Scler Relat Disord. 2017. PMID: 29055452
Alemtuzumab depletion failure can occur in multiple sclerosis.
Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S, Giovannoni G, Schmierer K. Dubuisson N, et al. Among authors: marta m. Immunology. 2018 Jun;154(2):253-260. doi: 10.1111/imm.12879. Epub 2018 Jan 4. Immunology. 2018. PMID: 29247512 Free PMC article.
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study.
Gold J, Marta M, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L, Adiutori R, MacManus D, Yousry T, Schmierer K, Turner B, Giovannoni G. Gold J, et al. Among authors: marta m. Mult Scler Relat Disord. 2018 Aug;24:123-128. doi: 10.1016/j.msard.2018.06.002. Epub 2018 Jun 28. Mult Scler Relat Disord. 2018. PMID: 29990894 Clinical Trial.
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G, Turner BP, Marta M, Mathews J, Giovannoni G, Baker D, Schmierer K. Mao Z, et al. Among authors: marta m. Mult Scler J Exp Transl Clin. 2018 Jun 26;4(2):2055217318783767. doi: 10.1177/2055217318783767. eCollection 2018 Apr-Jun. Mult Scler J Exp Transl Clin. 2018. PMID: 30090639 Free PMC article.
186 results